Spesolimab in Pyoderma Gangrenosum

Summary

The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum. Pyoderma gangrenosum is a rare, inflammatory, autoimmune condition which results in ulceration of skin. The study will also investigate the body's immune response to the spesolimab (when the body detects and defends itself against substances that appear unknown and harmful).

Timeline

Start

2023-09-23

Primary completion

2025-01-14

Completion

2025-01-14

Outcome

Outcome not reported

Stopped (Business): “The funding sponsor terminated our study and will conduct a multicenter national study in its place.”

Drugs

Indications